Trial Profile
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Jul 2023
Price :
$35
*
At a glance
- Drugs Bintrafusp alfa (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Cervical cancer; Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors EMD Serono; EMD Serono Research & Development Institute; Merck Biopharma
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 17 Mar 2023 Results (n=83 expansion cohort of NCT02517398 patients with non-small cell lung cancer) assessing efficacy and safety of Bintrafusp Alfa in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors published in the Oncologist
- 08 Feb 2023 Results(As of May 15, 2020, n=32 ; from an expansion cohort of a phase I study) assessing efficacy of Bintrafusp Alfa in Patients with Pretreated Colorectal Cancer published in the Oncologist